A US Food and Drug Administration official says the agency is taking steps to plan for post-pandemic on-site inspections that could look slightly different than typical FDA audits that took place before anyone even heard of COVID-19.
But in the interim, domestic companies may be asked to participate in voluntary Remote Regulatory Assessments (RRAs).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?